

CYCLOSPORIN-CONTAINING PHARMACEUTICAL COMPOSITIONS

Patent number: AU607506B
Publication date: 1991-03-07
Inventor: KURIHARA KOZO; MURANO MASARU
Applicant: SANKYO CO
Classification:
- international: **A61K47/40; A61K47/40;** (IPC1-7): A61K47/40;
A61K37/02
- european:
Application number: AU19880017386 19880603
Priority number(s): JP19870140730A 19870604

[Report a data error here](#)

Abstract not available for AU607506B

Data supplied from the **esp@cenet** database - Worldwide

Application Id : 17386 / 88 Serial Number : 607506

Relevant Act	Patents Act 1990(Transitional)		
Date Application Keyed	15/06/88		
Status : Patent Sealed			
Application Type	Convention application		
Filing Date	03/06/88	Complete Filing Date	03/06/88
Country of origin	JAPAN		
Number of pages	18		
Number of CDROMS			
CDROM Presence			
Filing fee	215		
Earliest Priority Date	04/06/87	Australian OPI Date	22/12/88

Patentee Name
 Novartis AG
 Address : Lichtstrasse 35,
 CH-4002 Basel,
 Switzerland

Inventor Name
 Kozo Kurihara
 Masaru Murano

Invention Title
 Cyclosporin-containing pharmaceutical compositions

Full Title
 Cyclosporin-containing pharmaceutical compositions

ATTORNEY ADDRESS
 Griffith Hack
 GPO Box 4164
 SYDNEY NSW 2001

EXAMINATION DETAILS

Direction Date	20/07/89	Request Lodgement date	18/09/89
Request Type	Full examination following direction		
Request Fee Paid	260	Acceptance Postponed	
Deferment Date		First Report Date	21/06/90
Examiner J HANSON		Examination Section	S4
Date Sent to Exam	10/12/90	Further Report Date	
Search Results Requested		Search Results Received	
Abstract Requested		Abstract Received	
Re-exam request date			
International (Type) Search Results			

ACCEPTANCE DETAILS

Date Accepted	11/12/90	Acceptance Advert Date	07/03/91
Date FE Printed	08/02/91		
Acceptance Type	After full exam.	Opposition Date	
Applicant Ref 13093-BT:AMP/LT		Opposition Result	
Amend to Spec 2,3			
Amend to ApIn 1			
Amend to Drwg			
Final date for Acceptance	21/03/92		

Application Id : 17386 / 88 607506 status Serial Number : 607506

Date Sealed 23/07/91 Sealed Advertised Date 08/08/91
Accept Not Sealed Advert
Lapsed Advertised Date
Lapsed Type
Withdrawn Advertised Date
Withdrawn Type
Refused Advertised Date Ceased/Expired Advert

CHANGE OF PATENTEE DETAILS:

Assignment under S 187, Reg 19.1 : RECORD 1
Date of Request 31/01/01

Instrument Date(s): 03/08/99 Date of Registration 07/02/01

Instrument Details: Deed of Assignment Date Parties Notified 12/02/01

Enclosures Deed of Assignment
Interest Full
Scope Australia
Service Address Davies Collison Cave
Level 15
1 Nicholson Street
MELBOURNE VIC 3000

Old Name and Address:
Sankyo Company Limited
5-1 Nihonbashi
Honcho 3-chome Chuo-ku
Tokyo
Japan

New Name and Address:
Novartis AG
Lichtstrasse 35,
CH-4002 Basel,
Switzerland

FEE HISTORY

Paid Date	Paid to Date	Fee Paid	Payor Code	Reference
	03/06/90			INITIAL PERIOD
30/05/90	03/06/91	75	CP	
23/04/91	03/06/92	100	CP	
18/05/92	03/06/93	135	CP	
17/05/93	03/06/94	165	CP	
16/05/94	03/06/95	200	CP	
16/05/95	03/06/96	235	CP	
13/05/96	03/06/97	270	CP	
12/05/97	03/06/98	305	CJ	
18/05/98	03/06/99	345	CJ	
17/05/99	03/06/00	385	CJ	
15/05/00	03/06/01	430	CJ	
24/05/01	03/06/02	475	CJ	
29/04/02	03/06/03	525	NV	
14/05/03	03/06/04	650	NV	
12/05/04	03/06/05	700	NV	
10/05/05	03/06/06	800	NV	

PAEN02BE V3.51 PATENT ADMINISTRATION SYSTEM 14/03/06 11:18:16 Page 3

Application Id : 17386 / 88

Serial Number : 607506

607506 status

Last Agency Address
NOVARTIS AG
Patent and Trademark Dept
Klybeckstrasse 141
CH-4002 Basel
SWITZERLAND

PRIORITY DETAILS

Date	Application Number	Country
04/06/87	62-140730	JAPAN

IPC Mark	First
A61K 47/40 (2006.01)	Y
A61K 37/02 (1985.01)	

***** End of Application *****

AU-A-17386/88

<p>89-047015/07 SANKYO KK 04.06.87-JP:140730 (22.12.88) A61k-37/02 A61k-47 Compan. confg. cyclosporin and alpha-cyclodextrin - useful for suppressing the immune system, topical treatment of ocular symptoms of Behcet's syndrome etc. C99-020644</p>	<p>805 SANY 04.06.87 *AU 8817-386-A</p>
<p>Pharmaceutical compsn. comprises at least one cyclosporin (I) together with an amt. of α-cyclodextrin (aCD) or functional deriv. sufficient to solubilise (I) in water.</p> <p>USE</p> <p>For suppressing the immune system, for topical treatment of the ocular symptoms of Behcet's Syndrome, for treatment of herpetic keratitis and spring catarrh, and during kerato- plasty (I) also have antifungal and antiphlogistic activities.</p> <p>ADVANTAGE</p> <p>The water-soluble complex shows reduced tendency for (I) to separate out on contact with water, prevention of in-leach forms, and gives high bioavailability by oral admin. The complex can be formulated into an. compsn. showing reduced ocular irritation and systemic side effects on topical admin. to the eye.</p>	<p>8;2-C, 4-C2B1, 12-A2C, 12-D2B, 12-D7, 12-D8, 12-L4, 12-M2F</p> <p>MORE SPECIFICALLY</p> <p>(I) is cyclosporin A or a mixt. contg. this. The cyclodextrin is aCD, or its ester, ether, aminoalky- lated deriv., salt with an S-confg. acid, carboxyalkylated deriv., addn. cpd. with a mono- or disaccharide, or a polymer confg. aCD in its main chain or pendant to the main chain, esp. acetylated, maltosylated, methylated or aminoethyl- -aCD, or aCD sub. hate.</p> <p>The wt. ratio of (I): aCD (or deriv) is 1:0.5-1:1000, esp. 1:1-1:200.</p> <p>The compsn. is pref. in the form of an aq. soln. with a concn. of aCD of 13-130, esp. 20-130 mg/ml and a concn. of (I) of 0.1-2.0, esp. 0.2-1.5 mg/ml.</p> <p>EXAMPLE</p> <p>100mg cyclosporin and 10g aCD were dissolved in 50ml of water. The soln. was stirred at room temp. for 2 hrs. and millipore filtered. The filtrate was freeze-dried to give a lyophilised powder which was completely soluble in water equal to the vol. of filtrate to give a transparent soln. (Zipp 1762DAHdWgNo0/0).</p>
	<p>AU8817386-A</p>